BRIEF-Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00

June 22 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

  • CEMDISIRAN REGULATORY SUBMISSIONS ACCEPTED FOR REVIEW BY FDA AND EMA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG)

  • REGENERON PHARMACEUTICALS - EUROPEAN COMMISSION DECISION ON CEMDISIRAN EXPECTED IN SECOND HALF OF 2027

  • REGENERON PHARMACEUTICALS - PLANS REGULATORY FILING FOR CEMDISIRAN IN JAPAN IN EARLY 2027

  • REGENERON PHARMACEUTICALS - FDA TO REVIEW CEMDISIRAN NDA UNDER PRIORITY REVIEW WITH TARGET ACTION DATE NOVEMBER 2026

Source text: ID:nGNX5r0zrs

Further company coverage: REGN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.